



GEDEON RICHTER



Richter and HRA Pharma Expand their Marketing Agreement for Esmya® to Latin America

11 June 2013

BUDAPEST and PARIS – Gedeon Richter Plc. ('Richter') and Laboratoire HRA Pharma ('HRA Pharma') today announced that they have entered into a licensing agreement in connection with marketing rights of ulipristal acetate (UPA) for the treatment of benign gynaecological disorders with respect to the territories of the Americas, except for the USA and Canada. Esmya® being its lead product for this condition, Richter further expands market presence of this product in the treatment of uterine myoma to the dynamically growing Latin American region. No financial terms related to the agreement were disclosed.

UPA is a molecule with a significant therapeutic potential in the field of women's health. Following the acquisition of PregLem and its innovative product Esmya® in late 2010, Watson Pharmaceuticals, Inc. received exclusive licensing rights to develop and market Esmya® in the USA and in Canada. In December 2011, Richter obtained from HRA Pharma an extension of its geographical scope for Esmya® to the CIS and China, two key markets with a significant growth potential.

Richter and HRA Pharma are two like-minded companies joining forces to provide innovative treatments for benign gynaecological conditions to women on a global scale. With the today disclosed agreement Richter procured the distribution and marketing rights for Esmya® for most of the key pharmaceutical markets worldwide.

Ends

For further information:

Richter:

Katalin Ördög, Investor Relations +36 | 431 5680

Zsuzsa Beke, Public Relations +36 | 431 4888

HRA Pharma:

Karina Gajek +33 | 40 33 66 02

About Gedeon Richter Plc

Gedeon Richter Plc. headquartered in Budapest/Hungary, is a major pharmaceutical company in Central Eastern Europe, with an expanding direct presence in Western Europe. Richter's consolidated sales were approximately EUR 1.1 billion (USD 1.5 billion) while its market capitalization amounted to EUR 2.3 billion (USD 3.1 billion) in 2012. The product portfolio of the Company covers almost all important therapeutic areas, including gynaecology, central nervous system and

cardiovascular. Having the largest R&D unit in Central Eastern Europe, the Company's original research activity focuses on CNS disorders. With its widely acknowledged steroid chemistry expertise Richter is a significant player in the female healthcare field worldwide. Richter is also active in the scope of biosimilar product development.

About HRA Pharma

HRA Pharma, UPA licensor, still retains worldwide rights to the molecule for the treatment of benign gynaecological disorders including uterine myoma; the company is looking for marketing and distribution partners in parts of Asia, Australia, New Zealand, Turkey, Middle East and Africa. HRA Pharma is a specialty pharmaceutical company that designs products, devices and supporting services in niche areas of health and makes them available to doctors and patients worldwide. The company targets therapeutic gaps in the areas of reproductive health and endocrinology, and uses innovative marketing solutions and socially-conscious programs, such as contraception education in developing countries, to promote healthy management of drugs and diseases. Headquartered in Paris, France and with subsidiaries in Germany, Italy, Spain, France, the United Kingdom and Ireland, HRA Pharma has built a strong network of R&D, manufacturing, distribution and NGO partners which enables it to satisfy critical patient needs and improve patient health in over 50 countries across the globe. Visit www.hra-pharma.com for more information.